StockData
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. (ABOS) stock

ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30
$0.19−0.00 (-0.57%)

Close on Nov 19, 2026Market cap $13.98MP/E –Yield –

Acumen Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Acumen Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was -$87.95M. For fiscal 2025 it was -$115.63M. The highest annual figure on record is -$18.00M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$115.63M–
FY2024Dec 31, 2024-$86.23M–
FY2023Dec 31, 2023-$43.09M–
FY2022Dec 31, 2022-$35.31M–
FY2021Dec 31, 2021-$18.00M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$26.65M–
Q2 FY2026Jun 30, 2026-$18.08M–
Q1 FY2026Mar 31, 2026-$24.13M–
Q4 FY2025Dec 31, 2025-$19.10M–
Q3 FY2025Sep 30, 2025-$30.49M–
Q2 FY2025Jun 30, 2025-$31.84M–
Q1 FY2025Mar 31, 2025-$34.20M–
Q4 FY2024Dec 31, 2024-$27.22M–
Q3 FY2024Sep 30, 2024-$24.60M–
Q2 FY2024Jun 30, 2024-$16.55M–
Q1 FY2024Mar 31, 2024-$17.87M–
Q4 FY2023Dec 31, 2023-$8.33M–
Q3 FY2023Sep 30, 2023-$12.91M–
Q2 FY2023Jun 30, 2023-$11.67M–
Q1 FY2023Mar 31, 2023-$10.18M–
Q4 FY2022Dec 31, 2022-$11.24M–
Q3 FY2022Sep 30, 2022-$9.26M–
Q2 FY2022Jun 30, 2022-$6.50M–
Q1 FY2022Mar 31, 2022-$8.31M–
Q4 FY2021Dec 31, 2021-$3.67M–
Q3 FY2021Sep 30, 2021-$7.70M–

More Acumen Pharmaceuticals figures

See a number that looks wrong?